Study on the Phenotype Polymorphism of CYP3A4 Gene in Chinese Children with Acute Leukemia.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4376-4376
Author(s):  
Xiao-jun Yuan ◽  
Long-Jun Gu ◽  
Hui-jun Zhao ◽  
Jin-cai Zhao ◽  
Jing-Yan Tang ◽  
...  

Abstract In order to offer objective refering paramete for individualized chemotherapy, to clarify the distribution feature of CYP3A4 activity in Chinese children with acute leukemia and in healthy children, to explore the possible correlation between the activity of CYP3A4 gene and the predisposition or chemotherapy effect in acute leukemia children. High performance liquid chromatography (HPLC) was used to detecte the activity of CYP3A4 in 85 healthy children and 120 acute leukemia children, then analyzed the difference of phenotypebetween two groups. The activity coverage of CYP3A4 was 2.34~48.88 in healthy children and the average activity was 9.76±6.99. Among them, CYP3A4 activity was 11.88±8.88 in male group and 7.12±3.37 in female group, the former was obviously higher than the latter (P=0.0077). In less than 12-years group, CYP3A4 activity was 8.97±6.27, while it was 10.43±7.74 in more than 12-years group, there was no significant difference (P>0.05). The change scope of CYP3A4 activity was very large in children with acute lymphoblastic leukemia, from 2.00 to 585.72, the average activity was 53.52, with no dfference in sex and age. According to the clinical risk degree, the activity of CYP3A4 was 4.87±2.93 in standard-risk group, it was 31.63±19.20 in middle-risk group, the latter was significantly higher thanthe former (P=0.0004). Comparison based on WBC count at the beginning of preliminary diagnosis, the CYP3A4 activity was the lowest in WBC count less than 50 x 109/L group, it was second in the group of WBC count between 50 x 109/L to 100 x 109/L, and the activity was the highest in WBC count more than 100 x 109/L group. The mean activity of CYP3A4 in childern with acute lymphoblastic leukemia with P170 less than 5% was 17.56±13.44, while it was 87.62±49.28 in those children with P170 more than 5%Ä, there was statistic difference between the two group(P=0.022). The activity in those preliminary diagnosed children with BCR-ABL(+) or Ph (+) or t (4,11) abnormal karyotype (105.86±44.41) was higher than those with normal karyotype patients (47.61±22.63), P=0.0219. Comparison the activity of CYP3A4 between those chlidren with clinical presentation as prednisone good response (PGR) and those with prednisone poor response, the activity in former group (27.23±13.58) was obviously lower than that of latter group (114.12±48.39), P=0.0358. The average CYP3A4 activity in children with acute myelocytic leukemia (AML) was 13.97±10.84. Of them, it was 15.09±7.52 in AML children with diploid chromosome and only 2.95±1.39 in hypodiploidy group, obviously, the activity of former group higher than that of latter group (P=0.0132). The CYP3A4 activity was respectively 19.78±11.59 and 2.86±1.16 in normal LDH group and in increased LDH group, there was significant difference (P=0.0036). The AML children with exo-marrow infiltration when diagnosis, their CYP3A4 activity (6.50±3.05) was lower than those children with pure marrow infiltration (19.06±11.15), P=0.044. There may be no race difference between the CYP3A4 activity of Chinese healthy children and White people. Increased CYP3A4 activity has closed correlation with ALL risk factors. The general CYP3A4 activity in AML children group was lower than that of ALL chlidren group. Much higher or much lower CYP3A4 activity may produce adverse influence to individuals.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4436-4436
Author(s):  
Teresa Jackowska Ass ◽  
Robert Wasilewski ◽  
Elzbieta Górska ◽  
Maria Wasik ◽  
Teresa Loch

Abstract Background: To assess the effectiveness of vaccination against varicella in children with acute lymphoblastic leukemia (ALL). Methods: 105 children without a history of varicella, were qualified for immunization against varicella with VARILRIX (Oka-strain varicella vaccine). 48 children had ALL and 57 were healthy. 25 of the children with ALL were receiving maintenance therapy, 23 children were after chemotherapy. Results: White blood cells (WBC), lymphocytes, and sub-populations of T- and B-lymphocytes were compared in the healthy and leukemic children before and after vaccination. The ALL children had significantly lower counts of WBC and lymphocytes before vaccination. After vaccination there were no significant differences in the counts of WBC in the healthy and leukemic children. However the ALL children had significantly lower mean counts of lymphocytes. Before vaccination the leukemic children showed a significantly lowered percentage of T-lymphocytes with decreased CD4+ and increased CD8+, what resulted in a lowered CD4 to CD8 ratio. After vaccination, only increased numbers of T CD8+ lymphocytes and a lowered CD4 to CD8 ratio were present while there was no significant difference in CD4. In the healthy and leukemic children alike there was no statistically significant difference between B-lymphocytes (CD 19+) and NK cells. In 10 children (20%), out of the 48 ALL vaccines, varicelliform rash occurred ~1 month after immunization. No adverse effects we observed in healthy children. Seroconversion to varicella-zoster virus was higher in healthy children and ALL children who had skin rash after vaccination. Two ALL children and three healthy ones had varicella one-two years after the vaccination. Those children received only single vaccine doses (double vaccine doses received children above 12 years). Conclusion: Varicella vaccine was safe and immunogenic in leukemic children during maintenance and after chemotherapy.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3948-3948
Author(s):  
Oznur Yilmaz ◽  
Cetin Timur ◽  
Asim Yoruk ◽  
Muferet Erguven ◽  
Elif Aktekin ◽  
...  

Abstract In this study, we aimed to investigate epidemiologic factors in children with Acute Lymphoblastic leukemia (ALL). The parents of 105 children diagnosed and treated as ALL between the years 1997 –2007 in our Clinic of Pediatric Hematology-Oncology were questioned and results were compared with control group that consisted of 102 healthy children with similar age and gender. The mean age of the patients was 8.57 ± 3.95 years. The mean age at diagnosis was 5.87 ± 3.73 years. There was no significant difference between the groups in terms of type of delivery, birth weight, asphyxia at birth, resuscitation with high-concentration oxygen and ventilatory support (p>0.05). There was also no significant difference between the groups in terms of duration of breast feeding. The rate of exposure to infections prior to diagnosis was higher in control group (p:0.003). Besides that, the rate of going to nursery was also significantly higher in control group (p:0.014). There was no difference between the groups in terms of X-ray exposure (p>0.05). In conclusion over-protection from infectious agents in and delay in meeting with some specific agents seems to increase ALL risk. Infections in early infantile period can be protective against leukemia. There has to be more extended studies on this subject.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4334-4334
Author(s):  
Itsuro Jinnai ◽  
Tohru Sakura ◽  
Motohiro Tsuzuki ◽  
Yasuhiro Maeda ◽  
Noriko Usui ◽  
...  

Abstract Abstract 4334 BACKGROUD We designed a multicenter study (JALSG ALL 97) including an intensified consolidation program with dose-escalated doxorubicin (DOX) in order to improve outcome in adults with acute lymphoblastic leukemia (ALL) in pre-imatinib era. We reported here the efficacy and prognostic factors of mainly Philadelphia chromosome (Ph)-negative patients. METHODS From May 1997 to December 2001, patients (age ranges 15 - 64 years) with previously untreated ALL (excluding mature B-cell ALL) were consecutively registered in this study. We modified the standard induction program with five drugs; vincristine (VCR), daunorubicin, cyclophosphamide, prednisolone (PSL) and L-asparaginase and the maintenance program with daily 6-mercaptopurine, weekly methotrexate (MTX) and monthly pulses of VCR and PSL used in CALGB 8811 study. Consolidation therapy included eight courses featuring dose-intensified DOX and intermediate-dose MTX. The total dose of DOX in consolidation phase was 330 mg/m2. For patients with Ph or t(4;11), allogeneic stem cell transplantation (HSCT) was recommended during their first complete remission (CR), if donors were available; whereas for patients without Ph or t(4;11) there was no criteria for choosing HSCT. The 5-year overall survival (OS), the 5-year disease-free survival (DFS), and the prognostic factors were evaluated. RESULTS There were 404 eligible patients (median age, 38 years), of whom 256 were Ph-negative and 116 were Ph-positive. Of the eligible patients, 298 patients (74%) achieved CR. With a median follow-up time of 5.8 years, the estimated 5-year OS rate was 32% (95%CI: 27.1-36.9), and the 5-year DFS was 33% (95%CI: 26.8 - 38.2). The CR rates in Ph-negative and Ph-positive patients were 81% (n=208) and 56% (n=65), respectively. The 5-year OS in Ph-negative and Ph-positive patients were 39% and 15%, respectively. In Ph-negative patients, multivariate Cox analysis showed that older age, PS and WBC count were the independent prognostic factors for OS. The 5-year OS rates for patients younger than 35 years and a WBC count less than 30 × 109/L (risk group 1), for patients younger than 35 years and a WBC count above 30 × 109/L (risk group 2), for patients older than 35 years and a WBC count less than 30 × 109/L (risk group 3), and for patients older than 35 years and a WBC count above 30 × 109/L (risk group 4), were 51%, 29%, 33%, and 27%, respectively (P=0.0005). Of the 208 Ph-negative patients who achieved CR, 60 patients (29%) were underwent allogeneic-HSCT during their first CR (37 from a related donor and 23 from an unrelated donor), resulting that 8 (13%) died in remission, 16 (27%) relapsed, and 36 (60%) remained in continuous CR. The 5-year OS rate for the 60 patients was 63 %. Among them, the 5-year OS rates for the 31 patients of the risk group 1 (standard risk group) and for other 29 patients (high risk group) were 73% and 54%, respectively. Among 148 patients who did not receive allogeneic-HSCT during first CR, six (4 %) died in remission, 105 (71%) relapsed, and 37 (25%) remained in continuous CR. The 5-year OS rates for the 148 patients, for patients with standard risk, and for patients with high risk were 37%, 44% and 33%, respectively. CONCLUSION Result of this study was in the range of those reported by most large cooperative groups, but showed little improvement of adult Ph-negative ALL therapy. The prognostic factors for long term outcome of Ph-negative patients were similar to those in previous reported. This study also suggested that allogeneic-HSCT for Ph-negative patients in first CR might have contributed to the improvement of the outcome. Disclosures: No relevant conflicts of interest to declare.


PLoS ONE ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. e0245667
Author(s):  
Hee Young Ju ◽  
Ji Won Lee ◽  
Hee Won Cho ◽  
Ju Kyung Hyun ◽  
Youngeun Ma ◽  
...  

Background Large inter-individual variations in drug metabolism pose a challenge in determining 6-mercaptopurine (6MP) doses. As the last product of 6MP metabolism, DNA-thioguanine nucleotide (DNA-TGN) could reflect the efficacy of 6MP, especially in patients harboring variants in the 6MP metabolism pathway. The aim of this study was to investigate the clinical significance of DNA-TGN monitoring in Korean pediatric acute lymphoblastic leukemia (ALL) patients, focusing on the NUDT15 genotype. Methods The subjects of this study were patients who underwent ALL treatment with 6MP. Tests for the NUDT15 and TPMT genotypes were performed, and prospective DNA-TGN and erythrocyte TGN samples were collected after two weeks or more of 6MP treatment. DNA-TGN was quantified using the liquid chromatography-tandem mass spectrometry method. Results A total of 471 DNA-TGN measurements in 71 patients were analyzed, which ranged from 1.0 to 903.1 fmol thioguanine/μg DNA. The 6MP intensity demonstrated a significant relationship with DNA-TGN concentration (P<0.001). Patients harboring NUDT15 variants were treated with a lower dose of 6MP (P<0.001); however, there was no significant difference in DNA-TGN concentration when compared to patients carrying wild-type NUDT15 (P = 0.261). These patients also presented higher variation in DNA-TGN levels (P = 0.002) and DNA-TGN/6MP intensity (P = 0.019) compared to patients carrying wild-type NUDT15. DNA-TGN concentration did not show a significant correlation with WBC count (P = 0.093). Conclusions Patients harboring NUDT15 variants demonstrated similar DNA-TGN concentrations even at low doses of 6MP and showed high variability in DNA-TGN. Particularly in patients with NUDT15 variants who need a reduced 6MP dose, DNA-TGN could be applied as a useful marker to monitor the therapeutic effect of 6MP.


2021 ◽  
Vol 3 (1) ◽  
pp. 39-44
Author(s):  
Zainab Badr ◽  
Wijdan AL-Moosawi ◽  
Sadiq Ali

Background: Cancer angiogenesis demonstrates an important role in the progression and pathogenesis of blood malignant disorders including acute lymphoblastic leukemia (ALL). Vascular endothelial growth factor (VEGF)-A is one of the most effective elements of endothelial cell growth; it promotes vascular permeability of endothelial cells and provides the new vasculature with oxygen and nutrients. Higher VEGF-A levels in childhood acute lymphoblastic leukemia (ALL) is associated with poorer patient outcomes. Aim of the study: to assess the level of VEGF-A in plasma of children with ALL. Subject and method: Forty children with ALL and 40 healthy children as control were enrolled in this study conducted at the Oncology Unit in Basrah Children’s Hospital from Oct 2019 to March 2020. Plasma VEGF-A level was evaluated using ELISA assay. Results: The plasma level of VEGF-A is higher in ALL children than those in the control (p < 0.001). Moreover, the plasma VEGF-A level in the high-risk group (HRG) is higher than that in the standard risk group (SRG). Conclusion: The significantly higher level of plasma VEGF-A in ALL children compared to the healthy ones may demonstrate the role of VEGF-A in stimulating angiogenesis in pediatric ALL. Keywords: Angiogenesis, vascular endothelial growth factor-A, childhood acute lymphoblastic leukemia, acute lymphoblastic risk groups.


Author(s):  
Soheila Zareifar ◽  
Ali Alavi Shoushtari ◽  
Aida Abrari ◽  
Sezaneh Haghpanah

Background: Children with acute lymphoblastic leukemia (ALL) are prone to neurotoxicity and consequently neurocognitive function impairment mainly due to undergoing different treatment modalities. In the current investigation, neurocognitive function of children with ALL was compared to that of healthy children. Materials and Methods: In this cross-sectional study, 155 ALL and 155 age- matched healthy children in Shiraz, Southern Iran, were included and evaluated using Continuous Performance Test (CPT).  Results: Mean age of the patients was 9.9± 2.4 years. The number of wrong responses and duration of response did not lead to significant difference between healthy and affected children. In the age group less than 12 years old, the frequency of no-response was higher in the case group compared to control group both in boys and girls (P = 0.012, P = 0.006 respectively). In addition, in male patients younger than 12 years old, the number of correct responses was significantly less than that of  controls (P = 0.010). Patients underwent concurrent radiotherapy and chemotherapy needed significantly more time for responding compared to patients in whom chemotherapy were discontinued and were in remission (P=0.001). Conclusion: Based on the results, ALL children younger than 12 years old showed some defects in cognitive function. Moreover, it was more prominent in young boys compared to young girls. Regardless of the type of treatment regimens, early detection of neurocognitive disorders should be warranted in this high-risk population with more focus on boys and younger children. Psychological support and appropriate interventions can help improve cognitive function, reduce the disruption of education, and enhance the social and family relationships.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3950-3950
Author(s):  
Cetin Timur ◽  
Oznur Yilmaz ◽  
Asim Yoruk ◽  
Muferet Erguven ◽  
Timucin Imdadoglu ◽  
...  

Abstract In our study, we aimed to evaluate environmental and socio-economic conditions in children with Acute Lymphoblastic Leukemia (ALL) and to point at possible etiologic factors that can affect leukemia risk. The parents of 105 children diagnosed and treated as ALL between the years 1997 –2007 in our clinic of Pediatric Hematology-Oncology were questioned in terms of environmental and socio-economical factors and results were compared with control group that consisted of 102 healthy children with similar age and gender. Educational level and monthly income were similar between the groups. Occupational exposure of fathers to dust and chemicals were significantly higher in leukemia group (OR:2.00; %95 CI=1.41–3.50, p:0.015). Living near transformer stations (OR: 4.08; %95 CI= 1.3–12.76, p: 0.034) and high-voltage power lines (OR: 2.43; %95 CI= 1.05–5.63, p:0.01) is found to be associated with increased risk of leukemia in children. There was no significant difference in terms of living near base stations (p&gt;0.05). Exposure to industrial air pollution was significantly higher in leukemia group and was related to an elevated risk of ALL (OR: 26.77; %95 CI= 3.53–202.80, p:0.001). There was no significant difference in terms of exposure to insecticides and pesticides between the groups (p:&gt;0.05). In conclusion, leukemia is a disease with multi-factorial etiology that occurs as a result of interactions of genes and environment. The list of possible chemical, physical and biologic agents suspected to play a role in its etiology increase with developing technology and environmental pollution. However there are no sufficient data and more extended studies have to be carried out.


Author(s):  
Danar Pradipta Rani ◽  
Sarworini B Budiardjo ◽  
Margaretha Suharsini

 Objective: The objective of this research is to investigate the differences in salivary secretory immunoglobulin A (sIgA) levels between children with gingivitis who have acute lymphoblastic leukemia (ALL) and are in the maintenance phase of chemotherapy and the levels in healthy children with gingivitis.Methods: This study used cross-sectional and laboratory observation methods with 19 ALL children and 19 healthy children who all had mild gingivitis. Two mL of saliva were collected and stored at −200°C. Then, salivary sIgA levels were measured using the ELISA method.Results: The results indicate an insignificant difference (p>0.05) in salivary sIgA levels between the ALL children in the maintenance phase with the level of 21.38 (7.23–107.26) and 37.26 (11.24–135.63) for the healthy children.Conclusion: There is no significant difference in salivary sIgA levels between the ALL children in the maintenance phase and the healthy children.


2021 ◽  
Vol 20 (2) ◽  
pp. 97-110
Author(s):  
Yu. V. Olshanskaya ◽  
O. I. Soldatkina ◽  
E. N. Nikitin ◽  
N. M. Timofeyeva ◽  
A. N. A.Kazakova ◽  
...  

The detection of genetic markers associated with poor prognosis is crucial to the selection of an appropriate treatment plan for B-cell precursor acute lymphoblastic leukemia (BCP-ALL). A hypodiploid karyotype in patients with BCP-ALL has an unfavorable impact and serves as a criterion for the stratification of patients into a high-risk group. However, the survival rates of patients with a hypodiploid karyotype remain poor. Russian treatment protocols for childhood acute lymphoblastic leukemia do not include a hypodiploid karyotype in risk stratification criteria. In order to determine the prognostic value of a hypodiploid karyotype and the clinical characteristics of BCP-ALL in patients with a hypodiploid karyotype, we analyzed the survival rates of 2,700 patients included in a multicenter study. Our study was approved by the Independent Ethics Committee and the Scientific Council of the D. Rogachev NMRCPHOI of the Ministry of Healthcare of the Russian Federation. All patients underwent karyotyping and fluorescence in situhybridization (FISH) testing. A hypodiploid karyotype was detected in 27 patients. Eighteen out of 27 patients had a hypoploid clone (according to karyotyping results), 2 patients had a doubled near-haploid clone (according to karyotyping and FISH results); in 7 patients with a normal karyotype or in the absence of mitosis, hypodiploidy was determined only by FISH test. BCP-ALL with hypodiploidy is usually associated with increased WBC count at disease onset. The median WBC count in the study group was 24.2 (3.4–206.0) × 109/l vs 10.3 (0.2–1290.0) × 109/l in the control group. The number of patients with initial leukocytosis < 30 × 109/l in the study group was significantly lower than in the control group (p< 0.062). Remission was achieved in 26/27 patients. The event-free survival rates in patients with hypodiploidy were significantly lower than in those without hypodiploidy: 50 ± 11% vs 72 ± 8% (p< 0.0001). The overall survival was 64 ± 10% and 90 ± 1%, respectively (p< 0.0001). The cumulative incidence of relapse in patients with a hypodiploid karyotype was higher (42.6 ± 10.9%) than in the controls (22.3 ± 8.1%) (p< 0.0001). The patients who received more intense treatment for intermediate- and high-risk groups showed better survival rates than those in the standard-risk group: 62 ± 13% vs 40 ± 15% (р= 0.59); the cumulative incidence of relapse according to the risk group was 26.4 ± 12.1% and 60 ± 16.9%, respectively (р= 0.19).The highest risk of relapse was observed in a group that included patients with near-haploidy and low hypodiploidy (26–39 chromosomes; 52.9 ± 14.4%). The event-free survival in this group was 36 ± 13%. The results of treatment of patients with BCP-ALL and hypodiploidy according to the national guidelines turned out to be comparable to the international ones. Patients with BCP-ALL and hypodiploidy should be initially stratified to the most intense treatment arm. In order to identify patients with hypoploidy, standard karyotyping is required; where needed, it can be supplemented by FISH analysis


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5077-5077 ◽  
Author(s):  
Soyoon MIN ◽  
Hyery Kim ◽  
Juhee Shin ◽  
Jin Kyung Suh ◽  
Sung Han Kang ◽  
...  

Background: Acute pancreatitis during chemotherapy of acute lymphoblastic leukemia (ALL) is an often fatal complication which is mainly associated with asparaginase. Despite of the improvement of supportive care during treatment of ALL, the prediction of acute pancreatitis has not been feasible. The aim of this study was to identify the risk factors of acute pancreatitis in pediatric ALL patients. Patients and methods: This study included total 421 patients under 18 years old of age who were newly diagnosed with ALL and treated at Asan Medical Center Children's Hospital between January 2000 and December 2018. Patients in standard-risk group received a modified COG AALL0331 based treatment, and those in high-risk group received Korean multicenter high-risk ALL treatment. For national insurance coverage, native L-asparaginase was used as a first choice in all patients except patients who accepted the expanses of Pegylated-asparaginase (PEG). Patients who developed hypersensitivities to native asparaginase or PEGs, Erwinia-asparaginase was administered. Fibrinogen, triglyceride, amylase, lipase, and coagulation battery were checked before every asparaginases in all patients. The diagnosis and grading of acute pancreatitis were based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The cases of acute pancreatitis after relapse or allogenic hematopoietic stem cell transplantation were excluded. All the laboratory data were collected and analyzed retrospectively. Results: The incidence of acute pancreatitis in pediatric ALL was 3.3% (14 patients) and asparaginase associated acute pancreatitis was 2.8% (12 patients). Acute pancreatitis occurred in mainly in induction chemotherapy (n=8, 67%). Two patients were developed acute pancreatitis in consolidation chemotherapy, 1 in interim maintenance chemotherapy. Among 8 patients who developed acute pancreatitis in their induction chemotherapy, 1 patient was not associated with asparaginase. Among 14 patients, 2 patients were expired of disease progression and none of patient died of acute pancreatitis. Grade 2, 3 of acute pancreatitis patients were 6 and 8 respectively. There was no grade 5 acute pancreatitis. Eleven out of twelve patients who developed acute pancreatitis associated with asparaginase medication re-challenged asparaginase medication after experiencing acute pancreatitis. Among re-challenged patients, only 1 had second acute pancreatitis and discontinued asparaginase medication. There was no significant difference in incidence of acute pancreatitis with initial BSA, protein C, protein S, and age at diagnosis. Multivariate analysis identified prolonged activated partial thromboplastin time (aPTT) before acute pancreatitis in 1 week was significantly involved with risk factor of acute pancreatitis (p=0.013) Eight patients (67%) received a fresh frozen blood transfusion(FFP) before acute pancreatitis in a week. Conclusions: Prolonged aPTT and FFP transfusion are particularly at risk for acute pancreatitis in pediatric ALL patients. Cautious re-challenging asparaginase medication after experiencing grade 2 and grade 3 acute pancreatitis is needed. Early diagnosis and manage asparaginase-associated acute pancreatitis will contribute patients with sufficient effect of asparaginase medication. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document